International Journal of Cancer · 1995 · 151 citations · 19 references
PharmacyPharmacologyToxicologyChemotherapyHepatotoxicologyImmunotoxicologyHepatic ToxicityLiposomal FormulationsLiposome-based DeliveryMacrophage BiologyPhagocyte BiologyAnionic LiposomesDoxorubicin-based TherapyLiposome ToxicityLiposomesMacrophage ToxicityNeutral LiposomesPhagocytic ActivitySublethal Toxic Effects
Doxorubicin entrapped within conventional liposomes (200 nm in diameter; lip-Dox) has major toxic effects on liver macrophages of the rat for a considerable period of time following i.v. administration, with respect to both specific phagocytic capacity and cell numbers. At different time-points after injection of lip-Dox or free doxorubicin, radiolabeled, negatively charged, "empty" test liposomes were injected. Phagocytic capacity was determined by isolating the liver macrophages and measuring the amount of macrophage-associated radioactivity. Four subfractions of liver macrophages of different cell-size and with intrinsically different phagocytic capacity were isolated. Twenty-four hours after injection of lip-Dox, the phagocytic capacity of the larger-sized liver macrophages was strongly decreased. The relatively low intrinsic phagocytic capacity of the smaller-sized macrophages was only slightly impaired. Phagocytic capacity after injection of lip-Dox was nearly restored to control values after 14 days. Blood clearance of Klebsiella pneumoniae bacteria after pre-treatment with lip-Dox was strongly decreased. Pre-treatment with the free drug and/or placebo liposomes had no effect on phagocytic and bacterial blood-clearance capacity. A major depletion of the liver macrophage population was observed, as revealed by both macrophage isolation and histology. Only 2 weeks after injection of lip-Dox, the number of cells had returned to that seen in control animals. In view of the important host-defense functions of the liver macrophages, especially in the control of tumor growth and infection, the findings reported here should be taken into consideration when lip-Dox is to be administered in anti-tumor therapy.
19
B Portmann · Journal of Hepatology · 1998 · 561 citations
Prevention of chronic doxorubicin cardiotoxicity in beagles by liposomal encapsulation.
Erik Herman, A Rahman, V J Ferrans et al. · PubMed · 1983 · 163 citations
Pharmacy, Pharmacology, Toxicology +16
Initial clinical (phase I) trial of TLC D-99 (doxorubicin encapsulated in liposomes).
J. Wayne Cowens, Patrick J. Creaven, William R. Greco et al. · PubMed · 1993 · 136 citations